Michael Koslowski
Vorstandsvorsitzender bei Kling Biotherapeutics BV
Profil
Michael Koslowski is currently the Chief Executive Officer at Kling Biotherapeutics BV since 2022.
Prior to this, he worked as the Chief Medical Officer and Head of R&D at Gammadelta Therapeutics Ltd.
Dr. Koslowski holds a doctorate degree from Universität zu Köln and an undergraduate degree from Universität des Saarlandes.
Aktive Positionen von Michael Koslowski
| Unternehmen | Position | Beginn |
|---|---|---|
Kling Biotherapeutics BV
 Kling Biotherapeutics BV BiotechnologyHealth Technology Kling Biotherapeutics BV is a clinical-stage biotechnology company based in the Netherlands. The Dutch company has developed a pipeline that evaluates B cells in individuals with remarkable responses to cancer and infectious diseases. Kling Biotherapeutics' proprietary B cell immortalization platform enables rapid functional screening of antibodies, leading to the identification of several antibodies targeting novel epitopes and cancer-associated antigens with unique post-translational modifications. Michael Koslowski has been the CEO of the company since 2022. | Vorstandsvorsitzender | 12.12.2022 |
Ehemalige bekannte Positionen von Michael Koslowski
| Unternehmen | Position | Ende |
|---|---|---|
Gammadelta Therapeutics Ltd.
 Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Michael Koslowski
| Universität des Saarlandes | Undergraduate Degree |
| Universität zu Köln | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Kling Biotherapeutics BV
Kling Biotherapeutics BV BiotechnologyHealth Technology Kling Biotherapeutics BV is a clinical-stage biotechnology company based in the Netherlands. The Dutch company has developed a pipeline that evaluates B cells in individuals with remarkable responses to cancer and infectious diseases. Kling Biotherapeutics' proprietary B cell immortalization platform enables rapid functional screening of antibodies, leading to the identification of several antibodies targeting novel epitopes and cancer-associated antigens with unique post-translational modifications. Michael Koslowski has been the CEO of the company since 2022. | Health Technology |
Gammadelta Therapeutics Ltd.
Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Gammadelta Therapeutics Ltd. is developing the potential of gamma delta (?d) cells to create improved immunotherapy of cancer and other serious diseases. The company was founded by Raj Mehta in 2016 and is headquartered in London, the United Kingdom. | Health Technology |
